Annette Hood
Overview
Explore the profile of Annette Hood including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
54
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
OBrien T, Davey C, White S, Horine D, Wynter-Minott S, Hood A
Nephrol Nurs J
. 2024 Nov;
51(5):489-491.
PMID: 39503456
Effective poster presentations are important in disseminating research findings, evidence-based practice projects, and quality improvement initiatives to diverse audiences. Posters are widely presented to peers, stakeholders, and the broader community,...
2.
OBrien T, Hood A, Spalla King T, Brinkman B
Nephrol Nurs J
. 2023 Dec;
50(6):509-511.
PMID: 38112679
Implementing evidence-based practice in nursing is essential for connecting theoretical knowledge with practical patient care. The spirit of inquiry serves as the foundational step in the evidence-based practice process. Nephrology...
3.
Pan Y, Hood A, Ahmad H, Altwerger G
Ann Pharmacother
. 2023 Jan;
57(10):1162-1171.
PMID: 36651235
Background: Real-world data regarding the use of poly (ADP-ribose) polymerase (PARP) inhibitors in recurrent ovarian cancer patients with non-BRCA homologous recombination (HR) mutations or somatic BRCA mutations are lacking. Objective:...
4.
Jaber Chehayeb R, Hood A, Wang X, Miksad R, Schellhorn Mougalian S, Lustberg M, et al.
JAMA Netw Open
. 2022 Nov;
5(11):e2244204.
PMID: 36445704
Importance: Advances in treatment of metastatic breast cancer (MBC) led to changes in clinical practice and treatment costs in the US over the past decade. There is limited information on...
5.
Harrigan M, McGowan C, Hood A, Ferrucci L, Nguyen T, Cartmel B, et al.
Nutrients
. 2021 Nov;
13(11).
PMID: 34835986
The use of dietary supplements is common in the general population and even more prevalent among cancer survivors. The World Cancer Research Fund/American Institute for Cancer Research specifies that dietary...
6.
Kunst N, Wang S, Hood A, Mougalian S, DiGiovanna M, Adelson K, et al.
JAMA Netw Open
. 2020 Nov;
3(11):e2027074.
PMID: 33226431
Importance: The neoadjuvant treatment options for ERBB2-positive (also known as HER2-positive) breast cancer are associated with different rates of pathologic complete response (pCR). The KATHERINE trial showed that adjuvant trastuzumab...
7.
Dzimitrowicz H, Berger M, Vargo C, Hood A, Abdelghany O, Raghavendra A, et al.
J Clin Oncol
. 2016 Jun;
34(29):3511-3517.
PMID: 27298406
Purpose Ado-trastuzumab emtansine (T-DM1) is currently approved for treatment in patients with human epidermal growth factor receptor 2 (HER2)-positive, metastatic breast cancer (MBC) who previously received trastuzumab and a taxane....
8.
Hillerman W, Russell C, Barry D, Brewer B, Bianchi L, Cundiff W, et al.
Prog Transplant
. 2002 May;
12(1):30-5.
PMID: 11993067
Context: Rigorous candidate evaluation is paramount for estimating risk and long-term success with transplantation. In addition, because of increasing waiting times, patients are seeking listing at multiple centers or transferring...